Eli Lilly has marked another victory in their ongoing intellectual property dispute with Teva Pharmaceuticals over the patent for the migraine drug Ajovy. Eli Lilly was able to convince the Patent Trial and Appeal Board (PTAB) to invalidate Teva’s patent.
This development follows closely after the successful overturning of a $176.5 million verdict against Eli Lilly by a Federal Judge in Massachusetts. The invalidated patent and the reversed judgment present multiple wins for the pharmaceutical giant in this ongoing legal battle.
These legal successes for Eli Lilly are particularly noteworthy in the highly competitive landscape of migraine drug development and distribution. Intellectual property and patent disputes often play a significant role in determining market leaders, and Eli Lilly’s victories underscore the importance of robust legal strategies in securing market share.
For further detailed engagement with this case, the proceedings of the Patent Trial and Appeal Board’s decision can be found in the original article.